Rare Disease Trial, Recruiting NCT05361811 Sponsor: National Cancer Institute (NCI) Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT05361811
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to understand the study and are willing to sign a consent form agreeing to take part
  • You can read and speak English
  • You are 18 years old or older
  • You are a parent or legal guardian of a child under 18 who has been diagnosed with a RASopathy condition, such as NF1, Noonan Syndrome, Legius Syndrome, CFC, Costello Syndrome, or another related condition
  • The child with the RASopathy condition lives with you at least half of the time
  • You have access to a computer, smartphone, and internet, or you are willing to use a device provided by the study team
  • You score 15 or higher on a specific parenting stress questionnaire used by the study, meaning you are experiencing a moderate or higher level of parenting stress

Who may not be able to join:

  • Another caregiver from your household is already enrolled in this study (if two caregivers from the same home wish to participate, only one can formally enroll — the other may receive some study materials to use independently)
  • You have a psychiatric illness, cognitive difficulties, or other circumstances that are not well-controlled and that a study psychologist believes would make it difficult for you to fully take part in the study (confirm with trial site)
  • You are currently taking part in, or planning to join, another program specifically focused on reducing parenting stress during the time this study is running (note: getting help for other mental health concerns is still allowed, as long as parenting stress is not the main focus)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Staci M Peron, Ph.D., National Cancer Institute (NCI)

Phone: (240) 760-6025

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 January 2024
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility & Acceptability; Changes in PSS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov